How should a patient with a patent foramen ovale be managed?

Management of Patent Foramen Ovale

For patients under 60 years old with PFO and cryptogenic stroke after extensive workup excluding other causes, strongly recommend PFO closure plus antiplatelet therapy over antiplatelet therapy alone. 1

Clinical Context and Patient Selection

The management of PFO is highly context-dependent and differs dramatically based on whether the patient has had a cryptogenic stroke versus being an incidental finding.

For PFO with Cryptogenic Stroke (Age <60)

This is where the evidence is strongest and most actionable. The 2018 BMJ guideline provides clear, tiered recommendations based on patient preferences and contraindications 1:

Primary Recommendation:

• When anticoagulation is contraindicated or declined: STRONGLY recommend PFO closure plus antiplatelet therapy versus antiplatelet therapy alone (high-quality evidence) 1
• When all options are acceptable: Weakly recommend PFO closure plus antiplatelet therapy over anticoagulation therapy 1
• When closure is contraindicated or declined: Weakly recommend anticoagulation over antiplatelet therapy alone 1

Critical Prerequisites:

• Age under 60 years
• Documented cryptogenic ischemic stroke
• Extensive workup negative for other stroke etiologies (this is non-negotiable)
• No traditional cerebrovascular risk factors ideally 1

Evidence Supporting Closure

A 2025 pooled analysis of 6 trials (3,740 patients) demonstrated compelling mortality and morbidity benefits 2:

• Annualized stroke incidence: 0.47% with closure vs 1.09% with medical therapy
• Adjusted hazard ratio: 0.41 (95% CI, 0.28-0.60)
• Median follow-up: 57 months

The benefit is NOT uniform across all patients. Using the PASCAL classification system 2:

• PASCAL "probable" patients (younger, no vascular risk factors, high-risk PFO features): 90% relative risk reduction (HR 0.10), absolute risk reduction 2.1%
• PASCAL "unlikely" patients (older, vascular risk factors, no high-risk PFO features): No benefit from closure, only increased procedural risks

Risk Stratification Tools

RoPE Score

Incorporates age, stroke/TIA history, diabetes, hypertension, smoking, and cortical infarct on imaging 2:

• Score <3: PFO prevalence 23% (similar to general population)
• Score 9-10: PFO prevalence 77%

PASCAL Classification (Preferred)

This is the superior tool as it combines RoPE score with anatomical echocardiographic criteria (large shunt, atrial septal aneurysm) to classify PFO as "probable," "possible," or "unlikely" cause of stroke 2, 3

Diagnostic Workup

First-line screening (per 2026 Australian/New Zealand consensus) 3:

• Transcranial Doppler (TCD) bubble study - preferred where available
• Transthoracic echocardiography - alternative when TCD unavailable
• Transoesophageal echocardiography - for confirmation before closure consideration

Universal screening indicated for:

• Cryptogenic stroke patients ≤60 years
• Selective screening for >60 years with embolic stroke of undetermined source, absent vascular risk factors, and excluded atrial fibrillation 3

Procedural Considerations

Practical aspects of closure 1:

• Procedure duration: Under 2 hours
• Hospital stay: Usually 1 day
• Activity resumption: Within a few days
• Full recovery: Within a few weeks

Device-related complications:

• Atrial fibrillation/flutter: Significantly increased risk (RR 4.67) 4
• However, sensitivity analysis for Amplatzer device showed no increased atrial arrhythmia risk 4
• Other device/procedure-related adverse events occur but are generally manageable 1

Age-Related Caveats

Critical limitation for patients >60 years 1:

• Applicability is uncertain in older patients
• Fewer cryptogenic strokes caused by paradoxical emboli in this age group
• Expected smaller benefits with greater procedural harms
• Traditional cerebrovascular risk factors (diabetes, hypertension, hyperlipidemia) reduce the likelihood that PFO is causative

Incidental PFO (No Stroke History)

Do NOT screen for primary prevention 5. PFO is present in 20-25% of the general population and screening is not recommended.

Special circumstances requiring consideration:

• Pregnant women at increased paradoxical embolism risk
• Patients undergoing laparoscopic non-cardiac surgery
• Decompression sickness in divers
• Systemic deoxygenation syndromes
• These require individualized assessment with multidisciplinary heart-brain team evaluation 3, 6

Treatment Algorithm

1. Confirm cryptogenic stroke with comprehensive workup excluding other etiologies
2. Verify age <60 years (primary evidence base)
3. Calculate PASCAL classification (combines RoPE + anatomical features)
4. If PASCAL "probable": Strongly favor PFO closure + antiplatelet therapy
5. If PASCAL "possible": Consider closure based on patient discussion
6. If PASCAL "unlikely": Medical therapy preferred (anticoagulation > antiplatelet if no contraindications)
7. Mandatory multidisciplinary heart-brain team evaluation for all closure decisions 3

Common Pitfalls

• Closing PFO in older patients (>60) without high-risk features: Exposes to procedural risk without proven benefit
• Failing to exclude other stroke etiologies: PFO is common; correlation ≠ causation
• Ignoring anatomical features: Shunt size and atrial septal aneurysm presence significantly impact causality assessment
• Not using PASCAL classification: RoPE score alone is insufficient for optimal patient selection 3

The evidence strongly supports closure in well-selected young patients with cryptogenic stroke and high-risk PFO features, but appropriate patient selection using validated tools is essential to maximize benefit and minimize harm.